IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the Rhesus monkey

Biotechnology and Bioengineering

Volumn 105, Issue 3, 2010, Pages 627-635

  Boado, Ruben J ^a,b   Lu, Jeff Zhiqiang ^a   Hui, Eric Ka Wai ^a   Pardridge, William M ^b  

^a ArmaGen Technologies Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Blood brain barrier; Delivery systems; Monoclonal antibody

Indexed keywords

AFFINITY BINDING; ALZHEIMER'S DISEASE; AMYLOID PEPTIDES; AMYLOID PLAQUES; BLOOD-BRAIN BARRIER; BRAIN DELIVERY; BRAIN UPTAKE; CHINESE HAMSTER OVARY CELLS; CHO CELL; DELIVERY SYSTEMS; FUSION PROTEINS; HEAVY AND LIGHT CHAINS; IN-VIVO; INSULIN RECEPTORS; LIQUID FORMULATIONS; MONOCLONAL ANTIBODIES (MAB); PROTEIN A; RHESUS MONKEY; SERUM-FREE MEDIUM; SINGLE-CHAIN FV; THERAPEUTIC ANTIBODIES; TROJAN HORSE;

AFFINITY CHROMATOGRAPHY; ALLERGIES; AMPLIFICATION; BLOOD; CHROMATOGRAPHIC ANALYSIS; CLONING; GLYCOPROTEINS; MONOCLONAL ANTIBODIES; PEPTIDES; PHARMACOKINETICS; SURFACE PLASMON RESONANCE;

MERGERS AND ACQUISITIONS;

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; BOLTON HUNTER REAGENT I 125; HUMAN INSULIN RECEPTOR MONOCLONAL ANTIBODY SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY FUSION PROTEIN; HUMAN INSULIN RECEPTOR MONOCLONAL ANTIBODY SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY FUSION PROTEIN I 125; HYBRID PROTEIN; INSULIN RECEPTOR; METHOTREXATE; NOOTROPIC AGENT; PROTEIN A; RADIOPHARMACEUTICAL AGENT; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; CHO CELL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG UPTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART; IN VITRO STUDY; IN VIVO STUDY; LIVER; LUNG; NONHUMAN; RHESUS MONKEY; SPLEEN;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; CHO CELLS; CRICETINAE; CRICETULUS; GENE EXPRESSION; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INSULIN; IODINE RADIOISOTOPES; MACACA MULATTA; RECOMBINANT FUSION PROTEINS; STAINING AND LABELING; TRANSFECTION;

CRICETULUS GRISEUS; EQUIDAE; MACACA MULATTA; PRIMATES;

EID: 74849088013     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22576     Document Type: Article

References (23)

1. Boado RJ, Pardridge WM. 2009. Comparison of blood-brain barrier transport of GDNF and an IgG-GDNF fusion protein in the Rhesus monkey. Drug Metab Disp 37: (in press).
2. Boado RJ, Zhang Y, Pardridge WM. 2007a. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol Bioeng 97:1376-1386.
3. Boado RJ, Zhang Y, Xia CF, Pardridge WM. 2007b. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug Chem 18:447-455.
4. Boado RJ, Zhang Y, Xia CF, Wang Y, Pardridge WM. 2008. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng 99:475-484.
5. Boado RJ, Hui EK-W, Lu JZ, Pardridge WM. 2009. AGT-181: Expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J Biotechnol 144:135-141.
6. Coloma MJ, Lee HJ, Kurihara A, Landaw EM, Boado RJ, Morrison SL, Pardridge WM. 2000. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res 17:266-274.
7. Cummings BJ, Cotman CW. 1995. Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet 346:1524-1528.
8. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
9. De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, Scott DW, Martin W. 2008. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 112:3303-3311.
10. Holliger P, Hudson PJ. 2005. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126-1136.
11. Hui EK, Boado RJ, Pardridge WM. 2009. Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier. Mol Pharm 6:1536-1543.
12. Jancso G, Domoki F, Santha P, Varga J, Fischer J, Orosz K, Penke B, Becskei A, Dux M, Toth L. 1998. Beta-amyloid (1-42) peptide impairs blood-brain barrier function after intracarotid infusion in rats. Neurosci Lett 253:139-141.
13. Jicha GA. 2009. Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'? Expert Opin Biol Ther 9:481-491.
14. Lombardo JA, Stern EA, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ, Hyman BT. 2003. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci 23: 10879-10883.
15. Marvin JS, Zhu Z. 2005. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin 26:649-658.
16. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. 2000. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. J Am Med Assoc 283: 1571-1577.
17. Pardridge WM. 2008. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug Chem 19:1327-1338.
18. Pardridge WM, Boado RJ. 2009. Pharmacokinetics and safety in Rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery. Pharm Res 26:2227-2236.
19. Pardridge WM, Kang YS, Buciak JL, Yang J. 1995. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res 12:807-816.
20. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M. 2002. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298:1379.
21. Su GC, Arendash GW, Kalaria RN, Bjugstad KB, Mullan M. 1999. Intravascular infusions of soluble beta-amyloid compromise the blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage. Brain Res 818:105-1017.
22. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D. 2004. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1:24.
23. Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN, Morgan D. 2006. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 26:5340-5346.